undamentalytics Newsletter

Scienture Holdings, Inc. key statistics and ratios

In fiscal 2025, Scienture Holdings, Inc. had return on equity of -55.6%, an operating margin of -9867.9%, debt equal to 2.9% of equity and a current ratio of 2.89. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Scienture Holdings, Inc.: financial ratios, annual
Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Gross margin1.2%70.6%93.5%100.0%100.0%88.3%65.5%33.3%48.0%53.8%3.6%4.4%76.8%87.7%
Operating margin−218.0%−95.7%−4.7%−40.6%13.5%−2.3%1.7%−14.6%−53.5%−28.4%−322.4%<−999%<−999%<−999%
Net margin−218.8%−134.5%−38.4%−111.2%9.9%0.2%−3.8%−14.8%−53.8%−33.9%<−999%>999%<−999%<−999%
Free-cash-flow margin−89.5%——————−13.2%−26.2%——<−999%<−999%—
Return on equity—————3.4%−11.4%−39.6%−85.4%−153.2%—22.8%−55.6%−56.6%
Return on assets−517.8%−247.5%−68.8%−233.4%60.5%0.6%−7.3%−33.0%−68.3%−73.3%−219.7%15.4%−43.9%−44.2%
Asset turnover2.371.841.792.106.142.691.912.231.272.160.170.000.000.01
Current ratio1.452.200.300.231.161.707.3010.954.720.970.240.802.893.04
Debt to equity14.8%0.0%88.0%——61.8%5.4%—0.0%65.5%>999%7.2%2.9%—
Interest cover (operating income ÷ interest)n/mn/mn/mn/m2.5xn/m2.4xn/mn/mn/mn/mn/mn/mn/m
R&D as % of revenue———————————>999%453.3%304.2%
Capital spending as % of revenue1.1%——————0.2%0.2%——8.8%0.0%—
Free cash flow ÷ net income———————————−157.5%——
Dividends ÷ net income———————————163.9%——

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 3 checks passed · June 30, 2026
What it owns · $88m
Short-term assets $9mLonger-term assets $79m
What it owes, and who funded it · $88m
Short-term liabilities $3mLonger-term liabilities $21mShareholders' equity $64m
  • Short-term assets cover short-term liabilities $9m of assets due within a year against $3m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $9m short-term assets against $21m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$40m against $3m of interest.

From Scienture Holdings, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

29 /100

Weak moat

How hard Scienture Holdings's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -33.6% of total assets over 10 years.

  • Pricing power 12 / 20

    Gross margin has been a median 64.6%, moving by 28.0 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -26.3%; its worst year was -12824.7%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 2 of 9 years, at a median -29.4% of revenue.

  • Discipline 10 / 20

    The diluted share count rose 1267.4% over five years; stock-based pay has been a median 2.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (34 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: SCNX vs SXTPSCNX vs SXTCLPCN vs SCNXAKAN vs SCNX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Scienture Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Scienture Holdings, Inc.